Linical (2183) Q1 2027 earnings summary

Executive summary

• Consolidated net sales for the three months ended June 30, 2026, were ¥1,912 million, a 27.2% decrease year-over-year, with declines in Japan, the U.S., and Europe, but growth in Korea and Taiwan from new project acquisitions.

• Operating losses persisted on a consolidated basis, with losses in Japan, the U.S., and Europe, while Korea and Taiwan saw improved profitability.

• Net loss attributable to owners of parent was ¥636 million, versus a net profit of ¥176 million a year earlier.

• Comprehensive loss for the quarter was ¥583 million, compared to a loss of ¥204 million in the prior year.

Financial highlights

• Net sales for the quarter were ¥1,912 million, down from ¥2,626 million year-over-year.

• Gross profit declined to ¥55 million from ¥708 million year-over-year.

• Operating profit was a loss of ¥719 million, compared to a loss of ¥104 million in the prior year.

• Ordinary loss was ¥164 million, compared to ordinary income of ¥636 million in the prior year.

• Net income per share was negative ¥28.16, down from ¥7.83 in the previous year.

Outlook and guidance

• Full-year forecast projects net sales of ¥10,680 million, a 23.2% increase year-over-year.

• Operating profit is forecasted at ¥256 million, signaling a return to profitability, with net income per share projected at ¥7.97.

• Dividend per share is planned to remain at ¥8.00, consistent with the previous year.

• No changes to previously announced forecasts.